SCHEMBL16396606

SCHEMBL16396606

COC(=O)Cc1ccc(CN)cc1OCc1cccc(-c2cccc(CNC(=O)OC(C)(C)C)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 7/20 0.49
F11 P03951 3/20 0.49
TPSB2 P20231 3/20 0.49
PLG P00747 1/20 0.49
PLAU P00749 1/20 0.49
KLKB1 P03952 1/20 0.49
F7 P08709 1/20 0.49
ACACB O00763 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
ACACA Q13085 1/20 0.40
BRD4 O60885 2/20 0.40
CREBBP Q92793 1/20 0.40
HDAC1 Q13547 2/20 0.39
GLS O94925 3/20 0.39
AOC3 Q16853 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396196 0.92 BRD4 (0.40) CFDF11TPSB2PLGPLAU
SCHEMBL16397186 0.92 BRD4 (0.40) CFDF11TPSB2PLGPLAU
SCHEMBL16410528 0.89 MRGPRX4 (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL16397233 0.88 HDAC1 (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL16397752 0.88 BRD4 (0.40) CFDF11TPSB2PLGPLAU
SCHEMBL16397602 0.88 BRD4 (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL16410286 0.88 CFD (0.51) CFDF11TPSB2PLGPLAU
SCHEMBL16396681 0.87 BRD4 (0.37) CFDF11TPSB2PLGPLAU
SCHEMBL16396577 0.86 PDCD1 (0.43) CTSBCTSSCTSK
SCHEMBL16397598 0.86 BRD4 (0.39) CFDF11TPSB2PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB CFD 1/4885F11 17/4885TPSB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.